Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care
Open accessThe DOI matches its Crossref record; 196 of the 197 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To assess the accuracy in diagnosing heart failure of clinical features and potential primary care investigations, and to perform a decision analysis to test the impact of plausible diagnostic strategies on costs and diagnostic yield in the UK health-care setting. DATA SOURCES: MEDLINE and CINAHL were searched from inception to 7 July 2006. 'Grey literature' databases and conference proceedings were searched and authors of relevant studies contacted for data that could not be extracted from the published papers. REVIEW METHODS: A systematic review of the clinical evidence was carried out according to standard methods. Individual patient data (IPD) analysis was performed on nine studies, and a logistic regression model to predict heart failure was developed on one of the data sets and validated on the other data sets. Cost-effectiveness modelling was based on a decision tree that compared different plausible investigation strategies. RESULTS: Dyspnoea was the only symptom or sign with high sensitivity (89%), but it had poor specificity (51%). Clinical features with relatively high specificity included history of myocardial infarction (89%), orthopnoea (89%), oedema (72%), elevated jugular venous pressure (70%), cardiomegaly (85%), added heart sounds (99%), lung crepitations (81%) and hepatomegaly (97%). However, the sensitivity of these features was low, ranging from 11% (added heart sounds) to 53% (oedema). Electrocardiography (ECG), B-type natriuretic peptides (BNP) and N-terminal pro-B-type natriuretic peptides (NT-proBNP) all had high sensitivities (89%, 93% and 93% respectively). Chest X-ray was moderately specific (76-83%) but insensitive (67-68%). BNP was more accurate than ECG, with a relative diagnostic odds ratio of ECG/BNP of 0.32 (95% CI 0.12-0.87). There was no difference between the diagnostic accuracy of BNP and NT-proBNP. A model based upon simple clinical features and BNP derived from one data set was found to have good validity when applied to other data sets. A model substituting ECG for BNP was less predictive. From this a simple clinical rule was developed: in a patient presenting with symptoms such as breathlessness in whom heart failure is suspected, refer directly to echocardiography if the patient has a history of myocardial infarction or basal crepitations or is a male with ankle oedema; otherwise, carry out a BNP test and refer for echocardiography depending on the results of the test. On the basis of the cost-effectiveness analysis carried out, such a decision rule is likely to be considered cost-effective to the NHS in terms of cost per additional case detected. The cost-effectiveness analysis further suggested that, if likely benefit to the patient in terms of improved life expectancy is taken into account, the optimum strategy would be to refer all patients with symptoms suggestive of heart failure directly for echocardiography. CONCLUSIONS: The analysis suggests the need for important changes to the NICE recommendations. First, BNP (or NT-proBNP) should be recommended over ECG and, second, some patients should be referred straight for echocardiography without undergoing any preliminary investigation. Future work should include evaluation of the clinical rule described above in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, dapagliflozin reduced all-cause mortality (HR 0.83; 95% CI, 0.71-0.97)and improved symptoms, physical function, and quality of life in patients with HFrEF.491,492”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [491]
Experimental — accuracy not yet measuredIn the citing paper
“Therapy with dapagliflozin 10 mg o.d. vs. placebo reduced the risk of the primary outcome, a composite of worsening HF (hospitalization or an urgent visit resulting in i.v.therapy for HF) or CV death, by 26% (HR 0.74; 95% CI, 0.65-0.85).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [491]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,191
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure
Maisel, A. S., Krishnaswamy, P., Nowak, R. M., McCord, J., Hollander, J. E., Duc, P., Omland, T., Storrow, A. B., Abraham, W. T., Wu, A. H. B., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020233 · Cited by 3,362
The effect of digoxin on mortality and morbidity in patients with heart failure
(1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360801 · Cited by 3,016
Research works printed but not linked: 2
- AJ. Should general practitioners use the electrocardiogram to select patients with suspected heart failure for echocardiography? Int J Cardiol 1997;62:31–6.
- X-ray, radionuclide ventriculography and right heart catheterization. Eur Heart J 1989;10:1017–28.
Cited by
Items 501–510 of 510
Value of the Biomarkers in Evaluating the Prognosis of Heart Failure
Druteikaitė, K. (2022) · Lithuanian University of Health Sciences
Demographic and clinical profile of patients with heart failure at a tertiary care hospital
Gailson, L., Singh, A. K., Pradhan, A. K., Prajapathi, S., Choudhary, R., Bhandari, M., Vishwakarma, P., Shukla, A., Sharma, A., Chaudhary, G. K., et al. (2026) · World Journal of Cardiology · doi:10.4330/wjc.v18.i4.117928
Unveiling the gap in heart failure: a Brazilian Unified Health System study
Silva, N. V. E., Pileggi, V. N., Vitorasso, R. L., Vicentini, D., Bilevicius, E., Batista, V. C., & Picoli, R. M. (2026) · Journal of Global Health · doi:10.7189/jogh.16.04097
“Additionally, healthcare providers may encounter difficulties in interpreting diagnostic tests accurately, especially in cases where imaging and biomarkers yield inconclusive results or where comorbid conditions complicate the diagnostic process [ 21 , 22 ].”
Liu, C., Wang, J., Ding, S., & Li, Y. (2026) · JMIR Research Protocols · doi:10.2196/95071
“Patients entered the tree and were classified as true positive (TP), false negative (FN), false positive (FP), or true negative (TN) according to their test results and underlying disease status, consistent with previous diagnostic-strategy modeling approaches in primary care HF evaluation [20].”
Overlap Between Heart Failure and Menopause: Diagnostic Challenges and Clinical Implications
Kwan, T. N., Yan, A., Jain, P., Raju, H., & Muthiah, K. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.05.011 · Cited by 1
Diretriz Brasileira de Insuficiência Cardíaca – 2026
Simões, M. V., Moura, L. Z., Martins, S. M., Mourilhe‐Rocha, R., Danzmann, L. C., Neto, J. A. D. F., Marcondes‐Braga, F. G., de Oliveira, M. T., de Albuquerque, D. C., Freitas, A. F., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260830
Ud‐Din, S., Harvey, J., Barron, N. J., Watson, R. E. B., Reid, A. J., Wong, J. K. F., Herrick, S. E., & Dumville, J. C. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-122867
Rahman, M. T., Razu, I., Fatima, S. M., Mostaert, B. J., Hunger, B., Hossain, M. F., Correa, D., O’Malley, J. T., Khan, N. A., Zhang, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.22.760829
Guanylin peptides in heart failure
Narayan, H. (2013) · OpenGrey (Institut de l'Information Scientifique et Technique)
Metadata
- Authors
- Mant, J., Doust, J., Roalfe, A., Barton, P., Cowie, M., Glasziou, P., Mant, D., McManus, R., Holder, R., Deeks, J., Fletcher, K., Qume, M., Sohanpal, S., Sanders, S., & Hobbs, F.
- Affiliations
- University of Birmingham (GB)
- Bond University (AU)
- National Institutes of Health (US)
- University of Oxford (GB)
- Corresponding author
- Mant, J
- Venue
- Health Technology Assessment
- Published
- 2009-07
- Volume
- 13
- Issue
- 32
- Pages
- 1-207, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2075669100
- Cited by
- 498
- References
- 197
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 18 · 2023: 34 · 2022: 26 · 2021: 29 · 2020: 32 · 2019: 34 · 2018: 28 · 2017: 35 · 2016: 41 · 2015: 36 · 2014: 36 · 2013: 31 · 2012: 38
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Health Technology Assessment (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Bond University Research Portal (Bond University) (submittedVersion, other-oa)
- e-publications@bond (Bond University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Health Technology Assessment programme (05/06/01)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Health Professions › Health Information Management › Artificial Intelligence in Healthcare
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- heart failure diagnosis, diagnostic accuracy, dyspnea, brain natriuretic peptide, NT-proBNP, electrocardiogram, chest radiography, clinical prediction rules, cost-effectiveness, diagnostic approach, primary care, echocardiography, decision analysis, sensitivity and specificity, clinical features, edema, orthopnea, hepatomegaly
- MeSH terms
- Aged, Aged, 80 and over, Diagnosis, Differential, Female, Heart Failure, Heart Function Tests, Humans, Male, Middle Aged, Primary Health Care, State Medicine, Practice Guidelines as Topic, Natriuretic Peptide, Brain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.